MD PhD MSc, FESC | Interventional Cardiologist, Oslo, Norway | Clinical trialist, @UniofOxford alumni
Oslo, Norge
Joined August 2009
- Tweets1K
- Following413
- Followers722
- Likes1.3K
Pinned Tweet
Honored and proud to see our work sit in @NEJM! The patient is still in good health. Image of the week.
nejm.org/doi/full/10.1056/NE… – at Oslo, Norway
What is the convenience/cost/safety benefit of coronary CT angio based planning of PCI that would justify its use even if it resulted in 62,5% more target-vessel failures than regular PCI?
nejm.org/doi/full/10.1056/NE…
Øyvind H Lie retweeted
As TAVI expands to younger and healthier patients, valve durability has become an increasingly important consideration.
🎙️ In this #ACCEL Lite episode, Drs. @DLBHATTMD and @oyvlie examine the results of "ACASA-TAVI: Antithrombotic therapy after TAVI". ↪️ bit.ly/4AHtZ5w
Øyvind H Lie retweeted
🚨 ACASA-TAVI trial: DOAC monotherapy nearly halved subclinical leaflet thrombosis (HALT) after TAVI without increasing bleeding.
But HALT is a CT surrogate, the safety margin deserves scrutiny, and this study does not establish clinical benefit.
Here is what the result changes - and what it does not. 🧵 1/7
Øyvind H Lie retweeted
Dr. Øyvind Lie and Dr. C. Michael Gibson discuss the ACASA-TAVI trial: 12 months of NOAC monotherapy with FXa inhibitor reduced subclinical leaflet thrombosis and was non-inferior for bleeding, thromboembolic events, or death versus standard ASA 75 mg daily in TAVI patients aged 65-80. Watch video here: clinicaltrialresults.org/wp-…
Happy to discuss the findings and implications of @acasatavi with @CMichaelGibson! We are a little wiser, but much is still to be learned. @JAMA_current
ACASA-TAVI trial: NOAC monotherapy achieved non-inferiority for bleeding, stroke, MI, or death and reduced subclinical leaflet thrombosis compared to ASA 75 mg daily for TAVI patients aged 65-80. Download slides here: clinicaltrialresults.org/wp-…
Øyvind H Lie retweeted
🔥#ESCCongress🔥2026 Hot Lines: ACASA-TAVI - Antithrombotic therapy after TAVI
🔗pcronline.com/News/Congress-…
@ANazmiCalik provides his take on the results of this trial presented by Oyvind H. Lie at ESC Congress 2026 in Munich.
#interventionalcardiology #clinicalresearch #TAVR
Øyvind H Lie retweeted
Are we going to start DOAC post TAVR not DAPT? @djc795
Presented at #ESCCongress from @JAMA_current:
After #TranscatheterAorticValveImplant, factor Xa inhibitor non–vitamin K antagonist oral anticoagulant monotherapy reduced hypoattenuated leaflet thickening vs acetylsalicylic acid monotherapy.
ja.ma/46ufQdP
Øyvind H Lie retweeted
Presented at #ESCCongress from @JAMA_current:
After #TranscatheterAorticValveImplant, factor Xa inhibitor non–vitamin K antagonist oral anticoagulant monotherapy reduced hypoattenuated leaflet thickening vs acetylsalicylic acid monotherapy.
ja.ma/46ufQdP
Øyvind H Lie retweeted
#HOTLINE 7 #ESCCongress #TAVI,T AVI, TAVI....
🫀 PCI Timing related to #TAVI-PCI
🫀 tricuspid intervention (TRIC-I-HF)
🫀 Post-TAVI antithrombotics #ACASA & #NOTION-4
Evidence catching up to clinical practice @mmamas1973
Øyvind H Lie retweeted
The results of the ACASA-TAVI trial will be presented at the #ESCCongress in Munich. See you there! esc365.escardio.org/esc-cong…
Øyvind H Lie retweeted
Ikke la deg skremme denne gangen heller! Kunnskap er trygghet. @nff_info @nff_landslag @idrett aftenposten.no/meninger/deba…
Øyvind H Lie retweeted
ARVC & exercise-induced arrhythmogenic #cardiomyopathy (EiAC) have similar presenting phenotypes, but only ARVC progressed over time. Despite the “morphological reserve” in EiAC, both had high rates VT/VF. jacc.org/doi/10.1016/j.jcmg.…
#JACCIMG #cardiomyopathy #ARVC #cvImaging @oyvlie
Øyvind H Lie retweeted
Similar But Different: Exercise-Induced vs Mutation-Dependent Arrhythmogenic Cardiomyopathy jacc.org/doi/10.1016/j.jcmg.…
An honour to have our work discussed in an editorial by André La Gerche and Hein Heidbuchel in @JACCJournals #JACCIMG
Both ACASA-TAVI and NOTION-4 are soon to be reported, should teach us a lot! @didier_tchetche @DFCapodanno
Thanks for sharing @DFCapodanno
I personally still don’t know what to propose post TAVI. Apart from those with clear indications for DAPT or NOAC, I tend to stay with aspirin alone 🤷🏾♂️
@PCRonline
Øyvind H Lie retweeted
New in @JACCJournals #JACCIMG
RV structure/function deteriorated in #ARVC but remained stable in #EiAC.
Still, life-threatening VA were common in both.
✅ Stable morphology ≠ low risk.
👉 Highlights the need for proactive monitoring in athletes.
🔗 sciencedirect.com/science/ar……
Øyvind H Lie retweeted
This year’s summer seminar was one for the books with world class speakers @mvaduganathan and @oyvlie talking about the interaction between heart and kidney and how to interpret clinical trials! 🙏 thank you
Milestone on a Wednesday! @chrisdodgson @jonherstadMD
Inclusion in the ACASA-TAVI trial is closed! All participants have been randomized to NOAC or ASA following successful TAVI. We are one step closer to understanding optimal antithrombotic therapy after TAVI! @Oslounivsykehus @haukeland_no
A good day at @UniofOxford Sheldonian Theatre! The MSc in Clinical Trials comes highly recommended! Great experience😎
Øyvind H Lie retweeted
Progression of myocardial dysfunction and prediction of arrhythmic events in patients with exercise-induced arrhythmogenic cardiomyopathy, by @Linda_Soon_Ah, @oyvlie, and colleagues
@Oslounivsykehus
heartrhythmopen.com/article/…
It is reasonable to analyze a non-inferiority trial for superiority. Are beta blockers dead? #ESCCongress nejm.org/doi/full/10.1056/NE… – at Oslo, Norway
